EDSA's logo.
Ticker Symbol: EDSA

Edesa Biotech Inc

$6.79 - 20-12-2024 4 p.m. ET

Exchange: NASDAQ Currency: USD Asset Type: Common Stock CIK:0001540159

Company Profile

Edesa Biotech, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative treatments for inflammatory and immune-related diseases with clear unmet medical needs. The company's two lead product candidates, EB05 and EB01, are in later stage clinical studies. EB05 is a monoclonal antibody therapy that it's developing as a treatment for Acute Respiratory Distress Syndrome (ARDS) in COVID-19 patients. ARDS is a life-threatening form of respiratory failure, and the leading cause of death among COVID-19 patients. Edesa is also developing an sPLA2 inhibitor, designated as EB01, as a topical treatment for chronic allergic contact dermatitis (ACD), a common, potentially debilitating condition and occupational illness. EB01 employs a novel, non-steroidal mechanism of action and in two clinical studies has demonstrated statistically significant improvement of multiple symptoms in ACD patients. The company is based in Markham, Ontario, Canada, with a U.S. subsidiary located in Southern California.

Sector: Manufacturing
Industry: Pharmaceutical Preparation Manufacturing
Standard Industrial Classification Code (SIC code): 2834
Address: N/A
CEO: N/A
Tags:
  • Biotechnology
  • Health Technology
  • Pharmaceuticals: Major
  • Manufacturing
  • Pharmaceutical Preparation Manufacturing

Pricing

Last Updated: October 3, 2023 03:00 PM EST
Previous Close: $0.64
Change: -$0.03 ( -5.02%)
Days Range: $0.60 - $0.65
Beta: 0.59
52wk. High: $19.67
52wk. Low: $2.46
Ytd. Change -73.72%
50 Day Moving Average: $5.13
200 Day Moving Average: $6.04
Shares Outstanding: 21093654

Valuation

Market Cap: 1.4B
PE Ratio: -
EPS (TTM): 0

Dividends

Dividend Per Share (TTM): -
Dividend Yield (TTM): 0.00%
Ex-Dividend Date: N/A